Agoracom Blog Home

Posts Tagged ‘#Trials’

VIDEOS: Empower Clinics: Q&A with Steven McAuley | Answering Investor Questions | April 29, 2024

Posted by Paul Nanuwa at 12:15 PM on Tuesday, April 30th, 2024

Welcome to Empower Clinics’ Q&A series, where Steven McAuley personally addresses investor questions. He dives deep into Empower Clinics’ latest developments and future plans, providing valuable insights for potential investors. Don’t miss the chance to learn more about our company firsthand, and stay tuned for more enlightening discussions! Watch all episodes below.

PART 1

PART 2

PART 2, Cont’d

PART 3

PART 4

 

 

Empower Clinics Emerges: Unveiling Significant Growth and a Visionary Strategy to Reinvigorate Investor Confidence

Posted by Paul Nanuwa at 3:12 PM on Thursday, April 11th, 2024

As the clinical trials market propels towards an estimated value of USD 887.0 Billion by 2032, Empower Clinics stands at the forefront of harnessing these burgeoning opportunities. Amidst the industry’s dynamic landscape, Empower Clinics is strategically positioned to leverage its expertise and drive innovation in medical research and patient-centric initiatives.

Industry Outlook and Empower Clinics’ Trajectory

The clinical trials industry is witnessing unprecedented growth fueled by escalating demand for innovative therapies and treatments. Empower Clinics is poised to navigate this trajectory with precision, capitalizing on emerging trends and technological advancements to drive transformative change. As the industry evolves, Empower Clinics remains steadfast in its commitment to advancing medical research and delivering impactful solutions.

Voices of Authority

Industry leaders echo Empower Clinics’ strategic vision, recognizing the company’s pivotal role in shaping the future of clinical trials. With a focus on collaboration and innovation, Empower Clinics is poised to drive meaningful advancements that enhance patient outcomes and revolutionize healthcare delivery.

Empower Clinics’ FLASH Highlights

Empower Clinics is a healthcare company with a growing research and clinical trials division that is currently achieving early success in the Dallas and Los Angeles markets. It has already been awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company and the company has grown their active sites from 2 in the fall to 6 at present. Principal Investigators have increased from 6 to 14 with an active pipeline in motion.  That foundation of doctors and medical offices opens the door to potential major contract wins from pharmaceutical companies that need speed and smarts from partners like Empower to get their clinical trials completed.

Real-world Relevance

Empower Clinics’ impact extends beyond the laboratory, translating into tangible benefits for patients and stakeholders alike. By championing patient-centric approaches and leveraging advanced technologies, Empower Clinics is at the forefront of delivering transformative healthcare solutions that address pressing medical challenges.

Looking Ahead with Empower Clinics

As the clinical trials industry continues to evolve, Empower Clinics remains focused on its mission to drive innovation and improve patient outcomes. With a forward-thinking approach and a dedication to excellence, Empower Clinics is poised to unlock new opportunities and redefine the future of medical research and patient care.

Conclusion

In a landscape defined by unprecedented growth and innovation, Empower Clinics emerges as a leader in the clinical trials arena. As the industry continues to evolve, Empower Clinics stands ready to lead the charge towards a brighter, more innovative future.

YOUR NEXT STEPS

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics
Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile
Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

 

Empower Clinics Emerges from Stealth Mode: A Game-Changer in Healthcare Innovation

Posted by Paul Nanuwa at 3:49 PM on Monday, April 8th, 2024

Small Cap Clinical Trial Company Sets Stage for Significant Growth

Empower Clinics, a burgeoning force in the healthcare sector, has stepped out of regulatory-mandated stealth mode with a robust growth trajectory and an ambitious plan to restore shareholder value. Led by CEO Steven McAuley, the company is poised for substantial expansion in its research and clinical trials division, marking a pivotal moment in its journey towards industry prominence.

Unveiling the Vision

Empower Clinics is not just another player in the healthcare landscape; it’s a company with a grand vision and a strategic roadmap to revolutionize clinical trials. As it emerges from stealth mode, Empower brings to the forefront a compelling narrative of growth and innovation. With a focus on research and clinical trials, the company has swiftly garnered attention for its early successes in key markets such as Dallas and Los Angeles including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

Foundational Growth and Promising Prospects

Under McAuley’s leadership, Empower has made significant strides in expanding its operational footprint. From just two active sites in the fall, the company has scaled up to six active sites today. Moreover, the number of Principal Investigators has more than doubled, from six to fourteen. This exponential growth not only underscores Empower’s commitment to excellence but also sets the stage for potential contract wins from global pharmaceutical giants.

Seizing Opportunities in a Booming Market

Empower Clinics’ timing couldn’t be more opportune. With the global Clinical Trials Market projected to reach USD 92.45 billion by 2030, fueled by the burgeoning pharmaceutical, biotechnology, and medical device sectors, Empower is primed to capitalize on this burgeoning market. As demographics shift and medical research advances, the company stands at the forefront of innovation, poised to play a pivotal role in shaping the future of healthcare.

Insightful Interview: A Glimpse into Empower’s Strategy

In a compelling interview with AGORACOM, CEO Steven McAuley provided invaluable insights into Empower’s growth trajectory and strategic imperatives. From navigating regulatory challenges to positioning the company for sustainable growth, McAuley’s vision and leadership shine through, offering shareholders and investors a glimpse into the company’s promising future.

Empower Clinics: A Signal of Hope in Healthcare Innovation

As Empower Clinics emerges from stealth mode, it ushers in a new era of innovation and growth in the healthcare sector. With a steadfast commitment to excellence, a robust foundation of operational success, and a visionary leadership team at the helm, the company is well-positioned to unlock tremendous value for shareholders and stakeholders alike.

Conclusion: Charting a Path to Success

Empower Clinics’ journey from stealth mode to growth mode signifies a significant milestone in its evolution as a player in the healthcare industry. With a compelling business model, a strategic focus on research and clinical trials, and a deep commitment to driving shareholder value, Empower is poised to redefine the future of healthcare innovation. As investors and stakeholders alike rally behind the company’s vision, the future looks brighter than ever for Empower Clinics and its pioneering approach to healthcare transformation.

YOUR NEXT STEPS

Visit $EPW HUB On AGORACOM: https://agoracom.com/ir/EmpowerClinics
Visit $EPW 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/EmpowerClinics/profile
Visit $EPW Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/EmpowerClinics/forums/discussion

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit https://agoracom.com/terms-and-conditions

CLIENT FEATURE: $VERT.ca Vertical Exploration – Developing the St. Onge Wollastonite Project $TORR.ca $FA.ca

Posted by AGORACOM at 12:29 PM on Friday, April 26th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
https://upload.wikimedia.org/wikipedia/commons/thumb/8/80/WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg/220px-WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg
Wollastonite
  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calciuminosilicatemineral that may contain small amounts of iron, magnesium, and manganese substituting for calcium
  • Wollastonite is used primarily in ceramics, friction products (brakes and clutches), metalmaking, paint filler, and plastics.
  • Located close to Saguenay Port and year round shipping access

St-Onge-Wollastonite Deposit: Resource Classification

This image has an empty alt attribute; its file name is image-1-600x96.png

Utilizing Wollastonite as A Soil Additive

  • Vertical is researching the use of Wollastonite as a soil additive for optimizing marijuana growth
  • Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC
  • Phase Three trials measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium

Hub on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: $VERT.ca Vertical Exploration – Developing the St. Onge Wollastonite Project $TORR.ca $FA.ca

Posted by AGORACOM at 1:00 PM on Friday, April 12th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
https://upload.wikimedia.org/wikipedia/commons/thumb/8/80/WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg/220px-WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg
Wollastonite
  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calciuminosilicatemineral that may contain small amounts of iron, magnesium, and manganese substituting for calcium
  • Wollastonite is used primarily in ceramics, friction products (brakes and clutches), metalmaking, paint filler, and plastics.
  • Located close to Saguenay Port and year round shipping access

St-Onge-Wollastonite Deposit: Resource Classification

This image has an empty alt attribute; its file name is image-1-600x96.png

Utilizing Wollastonite as A Soil Additive

  • Vertical is researching the use of Wollastonite as a soil additive for optimizing marijuana growth
  • Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC
  • Phase Three trials measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium

Hub on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: $VERT.ca Vertical Exploration – Developing the St. Onge Wollastonite Project $TORR.ca $FA.ca

Posted by AGORACOM at 12:20 PM on Friday, March 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
https://upload.wikimedia.org/wikipedia/commons/thumb/8/80/WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg/220px-WEZUWIAN_WOLLASTONIT_ANDRADYT_2.jpg

WOLLASTONITE

  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calcium inosilicate mineral that may contain small amounts of iron, magnesium, and manganese substituting for calcium
  • Wollastonite is used primarily in ceramics, friction products (brakes and clutches), metalmaking, paint filler, and plastics.
  • Located close to Saguenay Port and year round shipping access

St-Onge-Wollastonite Deposit: Resource Classification

Utilizing Wollastonite as A Soil Additive

  • Vertical is researching the use of Wollastonite as a soil additive for optimizing marijuana growth
  • Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC
  • Phase Three trials measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium

Hub on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

Vertical Exploration $VERT.ca Announces Wollastonite Research and Development Results

Posted by AGORACOM at 9:00 AM on Tuesday, February 5th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png
  • Successful completion of Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive
  • Phase Three trials BCBD measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • Optimal results occurred with an admixture rate of 10% to 15% Wollastonite to the growth medium

VANCOUVER, BC / February 5, 2019 / VERTICAL EXPLORATION INC. (TSX-V: VERT) (“Vertical” or the Company”) is pleased to announce the successful completion of Phase Three trials involving cannabis grown with wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC. The positive Phase Three trials build on the success of Phase Two Trials, which included samples of marijuana grown with 15% wollastonite from the Company’s St. Onge project being entered in an international growers’ competition, winning first place overall for Best Flower at the August 2018 Kootenay Cannabis Cup in Cranbrook, BC. (see October 2, 2018 news release.)

In the Phase Three trials BCBD measured and recorded significant improvements in root mass, powdery mildew control and pest elimination. In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium. Most notably, powdery mildew, the most common fungal blight to affect Cannabis sativa, was virtually undetectable with wollastonite admixture above 10%. An admixture above 10% wollastonite also correlated with sharp reductions in the presence of thrips and fungus gnats, insect pests with a sub-soil life phase in which the wollastonite crystals lacerate and impale their soft bodies. At a microscopic level, wollastonite’s needle-like structure penetrates soft-bodied insect larvae and pupae, interrupting the life cycle without the use of pesticides. Wollastonite’s unique properties also allow it to break down into calcium, magnesium and silicon in a highly bio-available form that balances soil PH throughout the growth cycle – this allows the cannabis plants to uptake silicic acid and promotes strong cell walls that better resist insect feeding and spore penetration, supporting increased growth and elevated product yields.

“We recorded a dramatic elevation of overall health among plants grown with wollastonite,” stated Matthew Harvey, CEO of BCBD. “The wollastonite group produced consistently low levels of powdery mildew — little to none – appearing later in the growth cycle. Roots, meanwhile, showed extreme vigour, growing dense and white with no sign of yellowing. Root health indicates a plant’s ability to resist disease and to support high yields of high-quality of finished marijuana.

According to Mr. Harvey the findings of the Phase Three BCBD wollastonite study indicate a major financial implication for the cannabis industry, where a trend towards cultivation of expansive plant canopies creates a powerful incentive for effective and efficient methods of crop protection and production.

As Mr. Harvey explained, “Large-scale cultivators need every tool at their disposal to improve plant health and avoid crop losses – a 10% to 20% loss in crop production due to a preventable outbreak of a destructive fungal pathogen can equate to millions of dollars of lost product. Companies that take crop protection seriously are looking for cost-effective soil additives that not only nourish plants but build resilience against the pests and pathogens that threaten profits. Our findings show wollastonite to be a critical tool for both cannabis crop protection and top-end production in a market where quality is of vital importance. It is no longer acceptable to spray fungicides on marijuana: natural prevention is the key and wollastonite is the answer.

Vertical’s CEO Peter Swistak commented: “We are very excited by these excellent Phase Three results which prove that wollastonite is a very appealing natural growing additive for the cannabis industry because it couples crop protection with product improvement, resulting in a more natural and healthier product for consumers.”

With the highly successful completion of these Phase Three cannabis trials at BCBD, Vertical is now moving aggressively forward with its plans to test market its high-quality St. Onge wollastonite to both micro-producers and large-scale cannabis companies. Vertical believes that the cannabis industry offers significant revenue potential for the company and anticipates providing further updates on its cannabis testing and marketing efforts in the near future.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

ON BEHALF OF THE BOARD
Peter P. Swistak, President

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).

SOURCE: Vertical Exploration Inc.